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Abstract
Uridine-5′-diphosphoglucose (UDPG) activates the P2Y14 receptor, a neuroimmune system GPCR.
P2Y14 receptor tolerates glucose substitution with small alkyl or aryl groups or its truncation to
uridine-5′-diphosphate (UDP), a full agonist human P2Y14 receptor expressed in HEK-293 cells. 2-
Thiouracil derivatives displayed selectivity for activation of the human P2Y14 vs. the P2Y6 receptor,
such as 2-thio-UDP 4 (EC50 1.92 nM at P2Y14, 224-fold selectivity vs. P2Y6) and its β-propyloxy
ester 18. EC50 of β-methyl ester of UDP and its 2-thio analogue were 2730 and 56 nM, respectively.
β-t-Butyl ester of 4 was 11-fold more potent than UDPG, but β-aryloxy or larger, branched β-alkyl
esters, such as cyclohexyl, were less potent. Ribose replacement of UDP with a rigid North or South
methanocarba (bicyclo[3.1.0]hexane) group abolished P2Y14 receptor agonist activity. α,β-
Methylene and difluoromethylene groups were well tolerated at the P2Y14 receptor and are expected
to provide enhanced stability in biological systems. α,β-Methylene-2-thio-UDP 11 (EC50 0.92 nM)
was 2160-fold selective versus P2Y6. Thus, these nucleotides and their congeners may serve as
important pharmacological probes for the detection and characterization of the P2Y14 receptor.
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Introduction
Purine and pyrimidine mononucleotides and dinucleotides have a role as extracellular signaling
molecules, in addition to their diverse intracellular roles.1 The P2Y family of G protein-coupled
receptors (GPCRs) responds to various extracellular nucleotides to induce intracellular
signaling cascades.2-4 The P2Y14 receptor was identified initially as an orphan GPCR activated
by uridine-5′-diphosphoglucose (UDPG 1, Chart 1) and other endogenous UDP-sugars. This
Gi-coupled receptor is expressed in the brain and in dendritic cells,5 although no functional
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role has yet been clearly assigned in these tissues. The P2Y14 receptor also is expressed in the
placenta, adipose tissue, stomach, intestine, brain, spleen, thymus, lung, and heart.1 Thus, the
P2Y14 receptor is of potential therapeutic interest for modulation of the immune system,7 as
well as treatment of pain,8 diabetes,9 cystic fibrosis, and other pulmonary diseases.10,11
A current goal of our research is to identify and apply potent, selective, and stable P2Y14
receptor ligands to define the physiological role(s) of this receptor.12-14 Although the P2Y14
receptor initially was identified as a UDP-sugar-activated GPCR, we recently discovered that
UDP is at least as potent as UDP-glucose and other nucleotide sugars for activation of this
receptor.14 Thus, it is perhaps not surprising that our recent detailed SAR (structure activity
relationship) analyses with synthetic analogues of UDPG12,13 revealed that the glucose moiety
is the least restricted region of the structure for substitutions that maintain P2Y14 receptor
agonist potency. This realization, together with conclusions made from our recent SAR study
of UDP analogues at the P2Y6 receptor,15 suggests that β-phosphate-substitution in a new
series of UDP analogues might favor activation of the P2Y14 receptor. Therefore, with the
ultimate goal of identifying highly selective ligands for the P2Y14 and P2Y6 receptors, we have
synthesized a new series of β-phosphate-substituted analogues of UDP and compared the
potencies of these novel molecules as well as a number of previously prepared uracil nucleotide
analogues at the human P2Y14 and P2Y6 receptors. Although the glucose moiety of UDPG
was suggested to interact with multiple H-bonding and/or charged resides within the putative
binding site of the P2Y14 receptor, its deletion or substitution with smaller phosphoester groups
was tolerated at this receptor. Simple alkyl esters at this position and analogues of UDP
displayed highly potent agonist activity at the P2Y14 receptor. The effects of these
modifications to preserve and enhance potency at the P2Y14 receptor were additive with the
previously identified potency enhancing effect of 2-thio substitution of the uracil moiety,
achieving in some cases nanomolar and subnanomolar potency. Importantly, a number of these




The principal objective of this study was to structurally simplify the distal end of uracil
nucleotide sugars known to activate the hP2Y14 receptor and to combine potency-enhancing
modifications. By removing the glucose moiety of UDPG 1, this agonist is converted into UDP
3, which we recently discovered is a highly potent agonist of the hP2Y14 receptor.14,16 The
activities of analogues of 1 modified on the glucose moiety have been explored, but
intermediate structures and truncated analogues related to UDP have not been systematically
examined. We also were searching for leads for UDP analogues that might provide selectivity
at the P2Y14 receptor over the P2Y6 receptor.
Simple ester and 5′-diphosphate analogues of the hP2Y14 receptor agonist UDPG 1 and its 2-
thio derivative 2 were synthesized (Table 1). The only modifications of the nucleobase included
were thiocarbonyl or methoxyamino substitution of carbonyl groups of the uracil moiety, which
were studied previously in P2Y14 receptor recognition.12 Several of the analogues of UDP 3
studied here were reported in studies of SAR at the P2Y6 receptor.15,17,18 All of the nucleotide
analogues were prepared in their ammonium or triethylammonium salt form according to the
methods shown in Schemes 1 – 3 and tested in functional assays of the hP2Y14 and hP2Y6
receptors (Table 1).
The uridine-5′-diphospho alkyl or aryl derivatives were obtained by the following methods.
The corresponding alkyl or aryl monophosphate analogues were treated successively with
cation-exchange resin and tributylamine. To the solution of the alkyl or aryl monophosphate
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tributylammonium salt in DMF, commercially available uridine 5′-monophosphate
morpholidate 4-morpholine-N,N-dicyclohexylcarboxamidine salt was added to form
uridine-5′-diphospho-β-ester analogues (6, 14, 19 – 20, 22 – 24, and 26 – 30) in a condensation
reaction as shown in Scheme 1. 2-Thio UDP 4 and 4-thio UDP 5 were synthesized by using
the previously reported procedure.17 (N)-Methanocarba-UDP 8 and (S)-methanocarba-UDP
9 were synthesized using our previously reported procedures.15,19,20 α,β-Methylene-UDP 10
and α,β-difluoromethylene-UDP 12 were also prepared using our recently published
procedures or modifications thereof. 2-Thio-α,β-methylene-UDP 11 was prepared by the DCC
coupling of 2-thiouridine with methylenediphosphonic acid (Scheme 3).18 Compound 7 and
13 were synthesized by using a recently developed procedure.15
For the preparation of the 2- or 4-thiocarbonyl β-alkyldiphosphate esters (15 – 18, 21 and
25), we either synthesized the alkylmonophosphate (42 – 44)21 or obtained the commercially
available alkylmonophosphates (41, 45). The monophosphates were transformed to the
corresponding tributylammonium salts and were then activated with 1,1′-carbonyldiimidazole
in DMF for 5 h at room temperature followed by quenching of this reagent with methanol.
After removing the solvent, the residue was dissolved in DMF, and 2-thio or 4-thiouridine 5′-
monophosphate tributylammonium salt was added to obtain compounds 15 – 18, 21, and 25
as shown in Scheme 2. All the nucleotide analogues were characterized using HPLC, nuclear
magnetic resonance (1H NMR, 31P NMR), and high-resolution mass spectrometry.
Quantification of Pharmacological Activity
Inhibition of adenylyl cyclase was quantified in HEK-293 cells stably expressing the
hP2Y14 receptor. This cell line, as well as a P2Y14 receptor-expressing Chinese hamster ovary
(CHO) cell line and a P2Y14 receptor-expressing C6 rat glioma cell line that we recently
developed, provides a physiologically relevant test system since receptor-promoted responses
mediated through a natively expressed heterotrimeric G protein (Gi) and its natively expressed
effector protein (adenylyl cyclase) are quantified.14 We conclude that this system is much
preferable to assay methods, employed by us and others, which utilized COS-7 cells transiently
over-expressing the P2Y14 receptor with an engineered G protein, Gα-q/i protein (Gαqi5), that
allows coupling of Gi-coupled receptors to activation of phospholipase C (PLC), resulting in
inositol lipid hydrolysis.22-24
Although UDPG 1 is usually thought of as a specific agonist of the P2Y14 receptor, it also was
found to activate the P2Y2 receptor (EC50 ~ 10 μM). 13 We now report EC50 values for 1 of
0.40 μM and 16 μ M at the P2Y14 and P2Y6 receptor, respectively (Table 1). Therefore,
although selective for the P2Y14 receptor, UDPG also activates other P2Y receptors. Thus,
more potent and selective agonists, preferably with a simplified chemical structure, are needed
as pharmacological probes of the P2Y14 receptor.
UDP 3 and its 4-thio derivative 5 were moderately potent agonists at the hP2Y14 receptor. One
of the most potent P2Y14 receptor agonists in the current set of nucleotides was the 2-thio
derivative 4 of UDP, which displayed an EC50 value of 1.92 nM. Compound 4 was 83-fold
more potent than 3 as a P2Y14 receptor agonist and 230-fold selective for the P2Y14 receptor
in comparison to the P2Y6 receptor. Replacement of a terminal negatively charged oxygen of
3 with an uncharged methyl group in the phosphonate derivative 6 resulted in a molecule with
similarly weak potencies at the two receptors. The N4-methyloxy cytidine derivative 7 was 20-
fold less potent than 3 at the P2Y14 receptor and consequently displayed selectivity for the
P2Y6 receptor, at which its high potency has been described.15 This finding is consistent with
the reported weak P2Y14 receptor activity of the corresponding N4-methyloxy cytidine
analogue of UDPG.13
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Replacement of a ribose moiety of various P2Y receptor agonists with a sterically constrained
bicyclic ring has been used to establish the receptor-preferred conformation. Neither of the
conformationally constrained methanocarba analogues 8 (North, N) and 9 (South, S) of UDP
3 was active at the P2Y14 receptor. Consistent with these findings with analogues of 3, we have
already established that the corresponding (N) and (S) methanocarba analogues of UDPG were
both inactive at the P2Y14 receptor.13
The introduction of carbon-bridged substitutions of the phosphate moieties of P2 agonists has
led to greater stability in biological systems due to the inability of ectonucleotidases to cleave
these groups.1,27 Replacement of the bridging oxygen of the diphosphate group of UDP with
a methylene 10 or difluoromethylene 12 group was well tolerated at the P2Y14 receptor,
resulting in high potency with EC50 values of 11 and 63 nM, respectively. Indeed, the α,β-
difluoromethylene analogue 12 was >2000-fold selective for the P2Y14 receptor in comparison
to the P2Y6 receptor, at which it was inactive at the concentrations tested. Combining a carbon
bridge with a known potency-enhancing uracil modification in 2-thio-α,β-methylene analogue
11 resulted in unprecedented potency at the hP2Y14 receptor with an EC50 value of 0.92 nM.
The selectivity of 11 in comparison to the hP2Y6 receptor was 2160-fold. Combining the α,β-
difluoromethylene and 5-iodo modifications in 13 maintained equipotency to UDP 3 at the
P2Y14 receptor, which stands in contrast with the inactivity of 5-iodo-UDPG and suggests non-
identical modes of uracil binding to the receptor between the two series.12 However, 13 was
not selective for the P2Y14 receptor when compared to the P2Y6 receptor.
The native agonist 1 is a β-ester of the diphosphate moiety, which prompted us to explore the
potency of structurally simpler β-esters at the P2Y14 receptor. Since compound 14, modified
with a methyl ester group instead of glucose, weakly activated the P2Y14 receptor and was
inactive at the P2Y6 receptor, this methyl ester was combined with other modifications to probe
the effects on biological activity. The combination with the 2-thio modification in compound
15 increased potency by 42-fold. Thus, compound 15 was >180-fold selective for the P2Y14
receptor. The 4-thio modification in methyl ester 16 abolished and greatly reduced potency in
comparison to 15 at the P2Y14 and P2Y6 receptors, respectively.
In the 2-thio series, homologation of the alkyl ester group of 15 was tolerated at the P2Y14
receptor, with the ethyl 17 and propyl 18 derivatives both displaying EC50 values of ~40 nM
and >200-fold selectivity in comparison to the P2Y6 receptor. A 2-cyanoethyl group in 19 was
poorly tolerated at the P2Y14 receptor. Substitution of the β-methyl ester with a t-butyl ester
group in 25 produced an equipotent agonist, which was 8-fold more potent than the
corresponding 2-oxo analogue 24. The β-t-butyloxy ester of 2-thio-UDP 25 was 11-fold more
potent than UDPG. Introduction of a glyceryl moiety esterified through the 2-hydroxyl group
in 23 did not diminish the potency of 3, but an isomeric glyceryl ester 22 was 10-fold less
potent than 3.
Alkynyl ester derivatives 20 (2-oxo) or 21 (2-thio) were either 2-fold less potent or 16-fold
more potent, respectively, than 3 at the P2Y14 receptor. Compound 21 was >900-fold selective
in comparison to the P2Y6 receptor.
β-Aryloxy and cycloalkyloxy esters 26 – 30 of UDP were found to only weakly activate the
receptor, in the order of potency phenyl > 4-nitrophenyl > 3-chloro- and 4-methoxyphenyl >
cyclohexyl.
Discussion
In the present study, we have further expanded the range of potent P2Y14 receptor ligands
through a systematic exploration of the SAR of structurally simple analogues at this receptor,
particularly with respect to substitution of the glucose moiety with diverse alkyl moieties. We
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have found that the introduction of α,β-methylene and difluoromethylene groups is well
tolerated at the P2Y14 receptor. These carbon-bridged nucleotides, including α,β-methylene-
UDP with an EC50 value of 11 nM, are expected to display greater stability in biological
systems. Methylene-bridged nucleotides tend to have increased stability by impeding
breakdown by ecto-nucleotidases present on the cell surface,27-29 and thus, these carbon-
bridged diphosphate analogues have good potential for in vivo applications.
The 2-thio modification, but not the 4-thio modification of the uracil ring, tended to increase
potency and selectivity at the P2Y14 receptor in comparison to the P2Y6 receptor. The most
selective compounds (fold selectivity for P2Y14 in comparison to P2Y6) in the present study
were UDP analogues 4 (233), 11 (2160), 12 (>150), 15 (>180), 17 (>250), 18 (230), and 21
(>900). The most potent of these were 2-thio-UDP 4 and α,β-methylene-2-thio-UDP 11.
Compound 4 had a high potency at the P2Y14 receptor, with an EC50 value of 1.92 nM, and
the corresponding α,β-methylene analogue 11 was even twice as potent. Although it is a less
potent P2Y14 receptor agonist, difluoromethylene-UDP 12 did not activate the P2Y6 receptor
at the concentrations of analogue tested. Other compounds that displayed lesser selectivity for
the P2Y14 receptor were (fold): 25 (64), 23 (59), 24 (43), and 10 (31). Thus, the 2-thio
derivatives 4, 11, and their congeners may serve as important pharmacological probes for the
detection and characterization of the P2Y14 receptor.
It is now clear that the glucose moiety of 1 is not required for activation of the P2Y14 receptor;
although when it is present, there is a SAR pattern related to interaction of specific functionality
of this hexose moiety with the receptor.13,26 We conclude here that UDP and its analogues are
potent full agonists of the human P2Y14 receptor, consistent with our recent pharmacological
studies of this receptor stably expressed in three different cell lines that utilized native Gi
proteins for signal transduction.14 This finding contradicts with the original work of Fricks et
al. who reported that UDP is a partial agonist/competitive antagonist of the human P2Y14
receptor, while acting as a full agonist at the rat P2Y14 receptor.16 However, the latter study
quantified activity of a recombinant P2Y14 receptor transiently coexpressed with an unnatural
chimeric G protein, Gaq/i that couples Gi-activating receptors to activation of PLC-β isozymes.
It was suggested that this system favors “a conformation of the P2Y14-R..., which results in
ligand binding selectivities and agonist activities that are not altogether consistent with
activities of the receptor obtained when coupled to its cognate heterotrimeric G protein.” Thus,
the efficacy of UDP appears to be a function of the G protein signaling system activated by
the receptor.
In conclusion, we have identified new analogues of UDP and its simple esters that display
enhanced potency and selectivity for the P2Y14 receptor and which promise to be useful as
pharmacological tools to distinguish the effects of uracil nucleotides acting at P2Y14 versus
P2Y6 receptors. The nanomolar potency achieved in this series is until now unprecedented for
small molecular ligands of the P2Y14 receptor. It is now possible to examine these potent




1H NMR spectra were obtained with a Varian Gemini 300 spectrometer using D2O as a solvent.
The chemical shifts are expressed as relative ppm from HOD (4.80 ppm). 31P NMR spectra
were recorded at room temperature by use of a Varian XL 300 spectrometer (121.42 MHz);
orthophosphoric acid (85%) was used as an external standard.
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Purity and extent of reaction of nucleotide derivatives was checked using a Hewlett–Packard
1100 HPLC equipped with a Zorbax Eclipse 5 μm XDB-C18 analytical column (250 × 4.6
mm; Agilent Technologies Inc, Palo Alto, CA), linear gradient solvent system: 5 mM TBAP
(tetrabutylammonium dihydrogenphosphate)-CH3CN from 80:20 to 40:60 in 20 min, with a
flow rate of 1 mL/min (System A), or Zorbax SB-Aq 5 μm analytical column (50 × 4.6 mm;
Agilent Technologies Inc, Palo Alto, CA). Mobile phase: linear gradient solvent system: 5 mM
TBAP (tetrabutylammonium dihydrogenphosphate)-CH3CN from 80:20 to 40:60 in 13 min;
the flow rate was 0.5 mL/min (System B). Peaks were detected by UV absorption (254 nm)
with a diode array detector.
Purification of the nucleotide analogues for biological testing was carried out on (diethylamino)
ethyl (DEAE)-A25 Sephadex columns with a linear gradient (0.01–0.5 M) of 0.5 M ammonium
bicarbonate as the mobile phase. Some of the compounds were additionally purified by HPLC
with a Luna 5-μm RP-C18(2) semipreparative column (250 × 10.0 mm; Phenomenex,
Torrance, CA) and using a linear gradient solvent system of 10 mM TEAA (triethylammonium
acetate)-CH3CN from 100:0 to 95:5 (or up to 99:1 to 90:10) in 30 min, with a flow rate of 2
mL/min. The tested nucleotide derivatives were confirmed by HPLC to possess a ≥ 95% purity.
Compounds purified by HPLC were isolated as the triethylammonium salts. Compounds 41
and 45, other reagents, and solvents were purchased from Sigma-Aldrich (St. Louis, MO).
General Procedure for the Preparation of Uridine 5′-Diphosphoglucose Analogues
The appropriate alkyl or aryl monophosphate was first converted to its tributylammonium salt
form by the treatment with ion-exchange resin (DOWEX 50WX2-200 (H)), which upon
acidification of the supernatant was followed by addition of tributylamine until a basic pH was
reached. The aqueous solvent was removed by lyophilization, and the residue was used without
further purification. A solution in DMF (1.5 mL) of uridine 5′-monophosphate morpholidate
4-morpholine-N,N-dicyclohexylcarboxamidine salt (20 mg, 0.029 mmol) and the
corresponding monophosphate (0.035 mmol, tributylammonium salt was stirred at room
temperature for 2 days. After that the solvent was removed and the residue was purified by
ion-exchange column chromatography using a Sephadex-DEAE A-25 resin (with a linear
gradient (0.01-0.5 M) of 0.5 M ammonium bicarbonate as the mobile phase) to provide the
corresponding nucleotide as the ammonium salt. Some of the uridine 5′-diphosphoglucose
analogues were additionally purified by HPLC as described above.
Diphosphoric acid 1-β-methyl (C-P) 2-(uridine-5′-yl)ester, triethylammonium salt (6)
Compound 6 (4.0 mg, 23%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.96 (d, J = 8.1 Hz, 1H), 6.00 (d, J = 4.8 Hz, 1H), 5.97 (d, J =
7.8 Hz, 1H), 4.38 (m, 2H), 4.29 (m, 1H), 4.21 (m, 2H), 1.46 (d, J = 16.8 Hz, 3H); 31P NMR
(D2O) δ 17.82 (d, J = 23.9 Hz), −11.06 (d, J = 23.8 Hz); HRMS-EI found 401.0158 (M –
H+)−. C10H15N2O11P2 requires 401.0151; purity > 98% by HPLC. (System A: 13.3 min).
Diphosphoric acid 1-β-methyl ester 2-(uridine-5′-yl)ester, ammonium salt (14)
Compound 14 (3.9 mg, 30%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.97 (d, J = 8.1 Hz, 1H), 6.01 (dd, J = 3.6, 1.2 Hz, 1H), 5.97 (d,
J = 8.1 Hz, 1H), 4.38 (m, 2H), 4.29 (m, 1H), 4.20 (m, 2H), 3.66 (d, J = 11.4 Hz, 3H); 31P NMR
(D2O) δ −9.22 (d, J = 21.4 Hz), −11.03 (d, J = 21.4 Hz); HRMS-EI found 417.0087 (M –
H+)−. C10H15N2O12P2 requires 417.0100; purity > 98% by HPLC. (System A: 11.3 min).
Diphosphoric acid 1-β-(2-cyanoethyl)ester 2-(uridine-5′-yl)ester, ammonium salt (19)
Compound 19 (3.7 mg, 26%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.99 (d, J = 8.4 Hz, 1H), 5.99 (m, 2H), 4.89 (m, 2H), 4.26 (m,
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3H), 4.16 (dd, J = 12.9, 6.0 Hz, 2H), 2.87 (t, J = 6.07 Hz, 2H); 31P NMR (D2O) δ −11.18 (dd,
J = 42.8, 21.4 Hz); HRMS-EI found 456.0212 (M – H+)−. C12H16N3O12P2 requires 456.0209;
purity > 98% by HPLC. (System A: 12.8 min).
Diphosphoric acid 1-β-(3-butynyl)ester 2-(uridine-5′-yl)ester, triethylammonium salt (20)
Compound 20 (5.31 mg, 28%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.88 (d, J = 8.1 Hz, 1H), 5.98 (m, 2H), 4.41 (m, 1H), 4.21 (m,
3H), 4.08 (m, 1H), 3.83 (m, 2H), 2.53 (m, 3H),31P NMR (D2O) δ −9.61 (d, J = 16.5 Hz), −11.2
(m), HRMS-EI found 455.0257 (M – H+)−. C13H17N2 O12P2 requires 455.0265; purity > 97%
by HPLC. (System B: 6.89 min).
Diphosphoric acid 1-α-glycerol ester 2-(uridine-5′-yl)ester, ammonium salt (22)
Compound 22 (2.2 mg, 15%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.96 (d, J = 8.4 Hz, 1H), 5.60 (m, 2H), 4.40 (m, 2H), 4.26 (m,
3H), 3.99 (m, 3H), 3.68 (m, 2H); 31P NMR (D2O) δ −10.35 (d, J = 21.4 Hz), −10.97 (d, J =
20.8 Hz); HRMS-EI found 477.0315 (M – H+)−. C12H19N2O14P2 requires 477.0312; purity >
98% by HPLC. (System A: 13.6 min).
Diphosphoric acid 1-β-glycerol ester 2-(uridine-5′-yl)ester, triethylammonium salt (23)
Compound 23 (3.1 mg, 16%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.97 (d, J = 7.8 Hz, 1H), 6.01 (m, 1H), 5.98 (d, J = 7.8 Hz, 1H),
4.39 (m, 2H), 4.30 (m, 2H), 4.24 (m, 2H), 3.77 (m, 4H); 31P NMR (D2O) δ −10.89 (dd, J =
37.9, 21.4 Hz); HRMS-EI found 477.0302 (M – H+)−. C12H19N2O14P2 requires 477.0312;
purity > 98% by HPLC. (System A: 11.2 min).
Diphosphoric acid 1-β-tert-butyl ester 2-(uridine-5′-yl)ester, ammonium salt (24)
Compound 24 (4.4 mg, 31%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.99 (d, J = 7.8 Hz, 1H), 5.99 (m, 2H), 4.39 (m, 2H), 4.29 (m,
1H), 4.24 (m, 2H), 1.44 (d, J = 0.3 Hz, 9H); 31P NMR (D2O) δ −11.51 (d, J = 21.4 Hz), −14.73
(d, J = 21.4 Hz); HRMS-EI found 459.0565 (M – H+)−. C13H21N2O12P2 requires 459.0570;
purity > 98% by HPLC. (System A: 13.6 min).
Diphosphoric acid 1-β-cyclohexyl ester 2-(uridine-5′-yl)ester, ammonium salt (26)
Compound 26 (6.2 mg, 41%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 8.00 (d, J = 8.4 Hz, 1H), 6.00 (m, 2H), 4.40 (m, 2H), 4.30 (m,
1H), 4.24 (m, 2H), 4.20 (m, 1H), 1.97 (m, 2H), 1.72 (m, 2H), 1.50-1.10 (m, 6H); 31P NMR
(D2O) δ −11.26; HRMS-EI found 485.0719 (M – H+)−. C15H23N2O12P2 requires 485.0726;
purity > 98% by HPLC. (System A: 11.8 min).
Diphosphoric acid 1-β-phenyl ester 2-(uridine-5′-yl)ester, ammonium salt (27)
Compound 27 (4.7 mg, 32%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.87 (d, J = 8.4 Hz, 1H), 7.36 (m, 2H), 7.19 (m, 3H), 5.93 (d, J
= 5.1 Hz, 1H), 5.81 (d, J = 8.4 Hz, 1H) 4.30 (m, 1H), 4.25 (m, 2H), 4.20 (m, 1H), 4.15 (m,
1H); 31P NMR (D2O) δ −11.11 (d, J = 21.5 Hz), −15.74 (d, J = 20.8 Hz); HRMS-EI found
479.0247 (M – H+)−. C15H17N2O12P2 requires 479.0257; purity > 98% by HPLC. (System A:
13.1 min).
Diphosphoric acid 1-β-(4-nitrophenyl)ester 2-(uridine-5′-yl)ester, ammonium salt (28)
Compound 28 (6.1 mg, 38%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 8.21 (d, J = 9.3 Hz, 2H), δ 7.76 (d, J = 7.83 Hz, 1H), δ 7.37 (d,
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J = 9.0 Hz, 2H), 5.92 (m, 1H), 5.69 (d, J = 7.5 Hz, 1H), 4.25 (m, 4H), 4.14 (m, 1H); 31P NMR
(D2O) δ −11.15 (d, J = 20.8 Hz), −17.12 (d, J = 20.8 Hz); HRMS-EI found 524.0110 (M –
H+)−. C15H16N3O14P2 requires 524.0108; purity > 98% by HPLC. (System A: 13.7 min).
Diphosphoric acid 1-β-(3-chlorophenyl)ester 2-(uridine-5′-yl)ester, ammonium salt (29)
Compound 29 (3.7 mg, 25%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.85(d, J = 8.1 Hz, 1H), 7.33 (m, 3H), 7.17 (m, 1H), 5.95 (d, J
= 4.2 Hz, 1H), 5.76 (d, J = 8.1 Hz, 1H), 4.29 (m, 4H), 4.18 (m, 1H); 31P NMR (D2O) δ −11.04
(d, J = 21.3 Hz), −16.18 (d, J = 21.3 Hz); HRMS-EI found 512.9867 (M – H+)−.
C15H16N2O12ClP2 requires 512.9854; purity > 98% by HPLC. (System B: 8.6 min).
Diphosphoric acid 1-β-(4-methoxyphenyl)ester 2-(uridine-5′-yl)ester, ammonium salt (30)
Compound 30 (3.3 mg, 21%) was obtained as a white solid following the general
procedure. 1H NMR (D2O) δ 7.82 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.7 Hz, 2H), δ 6.93 (d, J =
8.7 Hz, 2H), 5.95 (d, J = 4.8 Hz, 1H), δ 5.77 (d, J = 8.1 Hz, 1H), 4.29 (m, 4H), 4.16 (m,
1H); 31P NMR (D2O) δ −11.04 (d, J = 21.3 Hz), −15.37 (d, J = 21.3 Hz); HRMS-EI found
509.0362 (M – H+)−. C16H19N2O13P2 requires 509.0353; purity > 98% by HPLC. (System B:
8.84 min).
General procedure for the preparation of diphosphoric acid 1-alkyl ester 2-(thio uridine-5′-
yl)ester (15-18, 21, and 25)
Monophosphates (42-44) were prepared from the corresponding alcohols (37-39) using a
published procedure,21 and the spectral data were consistent with the assigned structures.
Each of the prepared monophosphates (42-44)21 or commercially available monophosphates
(41, 45) was transformed to its tributylammonium salt by treatment with ion exchange resin
followed by the addition of tributylamine. 1,1′-carbonyldiimidazole (10 mg, 0.06 mmol) was
added to the alkyl monophosphate tributylammonium salts (0.017 mmol) (41-45) in DMF (1
mL). The reaction mixture was stirred at room temperature for 5 h. Methanol (1 mL) was added
and stirring was continued at room temperature for an additional 1 h. After removal of the
solvent, the residue was dried under high vacuum and dissolved in DMF (1.5 mL). 2-
Thiouridine 5′-monophosphate tributylammonium salt (34)12 (5.7 mg, 0.008 mmol) for 15,
17, 18, 21, and 25 or 4-thiouridine 5′-monophosphate tributylammonium salt (35)12 (5.7 mg,
0.008 mmol) for 16 was added to the reaction mixture and it was stirred at room temperature
for 2 d. After removal of the solvent, the residue was purified by the same method as general
procedure using Sephadex-DEAE A-25 resin. Compounds 16 and 21 were further purified by
HPLC to provide homogeneous products.
Diphosphoric acid 1-β-methyl ester 2-(2-thiouridine-5′-yl)ester, ammonium salt (15)
Compound 15 (0.82 mg, 22%) was obtained as a white solid following the general
procedure. 1H NMR 1H NMR (D2O) δ 8.15 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 3.6 Hz, 1H), 6.24
(d, J = 8.1 Hz, 1H), 4.43 (m, 1H), 3.34 (m, 3H), 4.24 (m, 1H), 3.66 (d, J = 11.7 Hz, 3H); 31P
NMR (D2O) δ −10.68 (dd, J = 21.5, 6.6 Hz), −11.05 (d, J = 21.4 Hz); HRMS-EI found 432.9886
(M – H+)−. C10H15N2O11P2S requires 432.9872; purity > 98% by HPLC. (System A: 12.9
min).
Diphosphoric acid 1-β-methyl ester 2-(4-thiouridine-5′-yl)ester, triethyl ammonium salt (16)
Compound 16 (0.91 mg, 18%) was obtained as a white solid following the general
procedure. 1H NMR 1H NMR (D2O) δ 7.9 (d, J = 7.7 Hz, 1H), 6.69 (d, J = 4.3 Hz, 1H), 5.99
(d, J = 7.5 Hz, 1H), 4.40 (m, 3H), 4.30 (m, 2H), 3.69 (m, 3H); 31P NMR (D2O) δ −10.83 (d,
J = 21.3, Hz), −11.12 (d, J = 21.3 Hz); HRMS-EI found 432.9884 (M – H+)−.
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C10H15N2O11P2S requires 432.9872; purity > 98% by HPLC. (System B: 7.2 min in negative
absorbance).
Diphosphoric acid 1-β-ethyl ester 2-(2-thiouridine-5′-yl)ester, ammonium salt (17)
Compound 17 (7.7 mg, 20%) was obtained as a white solid following the general
procedure. 1H NMR 1H NMR (D2O) δ 8.22 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 3.0 Hz, 1H), 6.32
(d, J = 8.4 Hz, 1H), 4.49 (m, 1H), 3.39 (m, 3H), 4.29 (m, 1H), 4.09 (m, 2H), 1.33 (m,
3H); 31P NMR (D2O) δ −10.39 (t, J = 21.3, 42.7 Hz), −11.08 (d, J = 21.3 Hz); HRMS-EI found
447.0022 (M – H+)−. C11H17N2O11P2S requires 447.0028; purity > 98% by HPLC. (System
B: 7.09 min).
Diphosphoric acid 1-β-propyl ester 2-(2-thiouridine-5′-yl)ester, ammonium salt (18)
Compound 18 (0.91 mg, 23%) was obtained as a white solid following the general
procedure. 1H NMR 1H NMR (D2O) δ 8.21 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 3.1 Hz, 1H), 6.28
(d, J = 8.4 Hz, 1H), 4.47 (m, 1H), 3.41 (m, 3H), 4.26 (m, 1H), 3.95 (m, 2H), 1.65 (m, 2H); 0.96
(m, 3H); 31P NMR (D2O) δ −10.68 (d, J = 21.5, 4.), −11.10 (d, J = 21.3 Hz); HRMS-EI found
461.0145 (M – H+)−. C12H19N2O11P2S requires 461.0151; purity > 98% by HPLC. (System
B: 7.4 min).
Diphosphoric acid 1-β-(3-butynyl) ester 2-(2-thiouridine-5′-yl)ester, triethylammonium salt
(21)
Compound 21(1.18 mg, 22%) was obtained as a white solid following the general
procedure. 1H NMR 1H NMR (D2O) δ 8.12 (d, J = 8.1 Hz, 1H), 6.79 (d, J = 3.1 Hz, 1H), 6.23
(d, J = 8.1 Hz, 1H), 4.43 (m, 1H), 4.35 (m, 1H), 4.10 (m, 3H), 3.89 (m, 2H), 2.54 (m, 2H); 2.41
(m, 1H); 31P NMR (D2O) δ −9.63 (d, J = 21.3), −11.12 (d, J = 21.3 Hz); HRMS-EI found
471.0022 (M – H+)−. C13H17N2O11P2S requires 471.0035; purity > 97% by HPLC. (System
B: 6.9 min).
Diphosphoric acid 1-β-tert-butyl ester 2-(2-thiouridine-5′-yl)ester, ammonium salt (25)
Compound 25 (0.83 mg, 21%) was obtained as a white solid following the general
procedure. 1H NMR 1H NMR (D2O) δ 8.26 (d, J = 8.4 Hz, 1H), 6.68 (d, J = 3.0 Hz, 1H), 6.26
(d, J = 8.1 Hz, 1H), 4.41 (m, 1H), 3.36 (m, 3H), 4.27 (m, 1H), 1.47 (s, 9H); 31P NMR (D2O)
δ −11.00 (d, J = 21.3, Hz), −11.53 (d, J = 21.3 Hz); HRMS-EI found 475.0341 (M – H+)−.
C13H21N2O11P2S requires 475.0341; purity > 98% by HPLC. (System B: 7.16 min).
Preparation of 2-thiouridine-5′-α,β-methylene-diphosphate, triethylammonium salt (11)
A solution of 2-thiouridine (13 mg, 0.05 mmol) and DCC (30mg 0.15 mmol) was stirred in
DMF under a nitrogen atmosphere. Methylenediphosphonic acid (13 mg, 0.075 mmol) was
added and the stirring was continued for 48 h. The solvent was removed and the product was
purified by ion exchange column chromatography with a Sephadex-DEAE A-25 resin,
followed by semipreparative HPLC as described above.
Compound 11(11.8 mg, 33%) was obtained as a white solid. 1H NMR 1H NMR (D2O) δ 8.22
(d, J = 7.8 Hz, 1H), 6.65 (d, J = 3.2 Hz, 1H), 6.28 (d, J = 7.8 Hz, 1H), 4.47 (m, 2H), 4.37 (m,
2H), 4.26 (m, 1H), 1.47 (t, J = 19.2 Hz, 2H); 31P NMR (D2O) δ 16.70, 13.32 (m); HRMS-EI
found 416.9935 (M – H+)−. C10H15N2O10P2S requires 416.9923; purity > 98% by HPLC.
(System B: 7.04 min).
Assay of P2Y6 receptor-stimulated PLC activity
Activity at the hP2Y6 receptor was quantified in 1321N1 human astrocytoma cells stably
expressing this receptor. Twenty-four h after plating, the inositol lipid pool of the cells was
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radiolabeled by incubation in 200 μL of serum-free inositol-free Dulbecco's modified Eagle's
medium, containing 0.4 μCi of myo-[3H]inositol. No changes of medium were made
subsequent to the addition of [3H]inositol. Forty-eight h after transfection, cells were
challenged with 50 μL of the five-fold concentrated solution of receptor agonists in 200 mM
HEPES, pH 7.3, containing 50 mM LiCl for 20 min at 37 °C. Incubations were terminated by
aspiration of the drug-containing medium and addition of 450 μL of ice-cold 50 mM formic
acid. After 15 min at 4 °C, samples were neutralized with 150 μL of 150 mM NH4OH. [3H]
Inositol phosphates were isolated by ion exchange chromatography on Dowex AG 1-X8
columns as previously described.30
Assay of P2Y14 receptor-inhibited accumlation of 3′,5′-cyclic adenosine monophosphate
(cAMP)
Cell culture: Human embryonic kidney-293 cells stably expressing the hP2Y14-R (P2Y14-
HEK293 cells) were generated as previously described by Fricks et al.16 P2Y14-HEK293 cells
were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 1% Genticin (Gibco), and 1% antibiotic-antimocotic (Gibco) at 37°C in
a 5% CO2 environment.
cAMP accumulation: P2Y14-HEK293 cells were grown in 24-well plates and incubated with
1 microCi [3H]adenine/well in serum-free DMEM for at least 2 h prior to assay. Assays were
initiated by addition of HEPES-buffered, serum-free DMEM containing 200 microCi 3-
isobutyl-1-methyl-xanthine (IBMX) and 30 μM forskolin, with or without drugs, and
incubation continued for 15 min at 37°C. Incubations were terminated by aspiration of the
medium and addition of 450 mL ice-cold 5% trichloroacetic acid. [3H]cAMP was isolated by
sequential Dowex and alumina chromatography and quantified by liquid scintillation counting
as previously described by Harden et al. (53).
Data Analysis
Agonist potencies (EC50 values) were obtained from concentration-response curves by non-
linear regression analysis using the GraphPad software package Prism (GraphPad, San Diego,
CA). All experiments were performed in triplicate assays and repeated at least three times. The
results are presented as mean ± SEM from multiple experiments or in the case of concentration
effect curves from a single experiment carried out with triplicate assays that were representative
of results from multiple experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of two UDP-sugars (1, 2) that act as P2Y14 receptor agonists, UDP 3, a naturally
occurring ligand of the hP2Y14 receptor, and its analogue 2-thio-UDP 4.
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Synthesis of UDPG analogues including UDP β -esters. Reagents and conditions: (a)
ROPO3H2, DMF, rt.
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A) Synthesis of thio-UMP derivatives 34 and 35. Reagents and conditions: (a) (i) POCl3, proton
sponge, PO(OMe)3, 0°C (ii) 0.2 M triethylammonium bicarbonate, rt. B) Synthesis of thio-
UDP derivatives 15-18, 21, and 25. Reagents and conditions: (b) H3PO4, Pyridine, Et3N,
Ac2O (c) (i) CDI, DMF, rt; (ii) 5% TEA in 1/1 MeOH/H2O; (d) 2-thiouridine-5′-
monophosphate tributylammonium salt 34 or 4-thiouridine-5′-monophosphate
tributylammonium salt 35, DMF, rt.
Das et al. Page 16














Synthesis of α,β-methylene-2-thio-UDP 11. Reagents and conditions: (a) DCC, DMF, rt.
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(A) Activation of Gi-coupled P2Y14 receptor (left panel) was assessed by quantification of
inhibition of forskolin-stimulated [3H]cyclic AMP accumulation in HEK293 cells stabling
expressing the hP2Y14 receptor. Activation of the Gq-coupled P2Y6 receptor (right panel) was
assessed by quantification of [3H]inositol phosphate accumulation in 1321N1 human
astrocytoma cells stably expressing the hP2Y6 receptor by agonists Up2-OMe 14, 2-thio-Up2-
OMe 15, and its O-propyl ester 18 (B) Activation of Gi-coupled P2Y14 receptor (left panel)
was assessed by quantification of inhibition of forskolin-stimulated [3H]cyclic AMP
accumulation in HEK293 cells stabling expressing the hP2Y14 receptor. Activation of the
Gq-coupled P2Y6 receptor (right panel) was assessed by quantification of [3H]inositol
phosphate accumulation in 1321N1 human astrocytoma cells stably expressing the hP2Y6
receptor by methylene-bridged agonist 10, its 2-thio analogue 11, and the difluoromethylene-
bridged agonist 12.
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Table 1
In vitro pharmacological data for UDPG 1, UDP 3, and their analogues (nonsugar β-phosphoesters and other
derivatives of UDP) in the inhibition of cAMP formation at recombinant hP2Y14 receptors expressed in HEK-293
cells stably transfected with the hP2Y14 and in the stimulation of PLC at recombinant hP2Y6 receptors stably
expressed in 1321N1 cells. Unless noted: X, Y = O, Z = H.
Compound Modification Structure R = EC50, nMa
    UDP-sugars hP2Y14 hP2Y6
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Compound Modification Structure R = EC50, nMa
1 UDP-[1]glucose 400±90 16,000
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Compound Modification Structure R = EC50, nMa
2b 2-thio-UDP-[1]glucose, 11±5 >10,000c
    UDP analogues hP2Y14 hP2Y6
3 UDP HO 160±40 530±60
4 2-thio-UDP HO, X1 = S 1.92±0.69 447±100
5 4-thio-UDP HO, X2 = S 320±130 2360±710
6 Up2-β-Me-phosphonate R = CH3 4580±1560 8000±1630
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Compound Modification Structure R = EC50, nMa
7 N4-OCH3-CDP HO, X2 = N-OCH3 3320±1620 70±7b
8d (N)-methanocarba UDP (pure enantiomer) HO NE NE
9d (S)-methanocarba UDP (pure enantiomer) HO NE 42±8b
10 Up-CH2-p (α,β-methylene UDP) HO, Y = CH2 11±6 339±97
11 2-thio-Up-CH2-p (α,β-methylene-2-thio-UDP) HO, Y = CH2, X1 = S 0.92±0.09 1990±370
12b,e Up-CF2-p (α,β-difluoromethylene UDP) HO, Y = CF2 63±9 NEb
13 5-I-Up-CF2-p HO, Y = CF2, Z = I 142±74 127±24
    UDP β-esters hP2Y14 hP2Y6
14 Up2-OMe CH3O 2730±680 >10,000c
15 2-thio-Up2-OMe CH3O, X1 = S 56±19 >10,000c
16 4-thio-Up2-OMe CH3O, X2 = S NE 10,400±4200
17 2-thio-Up2-OEt CH3CH2O, X1 = S 39±20 >10,000c
18e 2-thio-Up2-OPr CH3(CH2)2O, X1 = S 40±6 9100±1430
19 Up2-O(CH2)2CN O(CH2)2CN 7460±2340 >10,000c
20 Up2-O(CH2)2C≡CH O(CH2)2C≡CH 480±161 1520±100
21 2-thio-Up2-O(CH2)2C≡CH O(CH2)2C≡CH, X1 = S 11.0±1.4 >10,000c
22 Up2-OCH2CHOHCH2OH OCH2CH(OH)-CH2OH 1600±600 >10,000c
23 Up2-OCH(CH2OH)2 OCH(CH2OH)2 167±32 >10,000c
24 Up2-OC(CH3)3 OC(CH3)3 252±93 10,800±1900
25 2-thio-Up2-OC(CH3)3 OC(CH3)3, X1 = S 32±1 2040±600
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Compound Modification Structure R = EC50, nMa
26 Up2-O -cyclohexyl 5160±1830 >10,000c
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Compound Modification Structure R = EC50, nMa
27 Up2-OC6H5 768±304 7400±860
28 Up2-OC6H4-4-NO2 1490±490 2760±810
29 Up2-OC6H4-3-Cl 1800±860 7370±530
30 Up2-OC6H4-4-OCH3 1900±490 >10,000c
NE - no effect at 10 μM.
a
Agonist potencies reflect stimulation of phospholipase C, unless noted, and were calculated using a four-parameter logistic equation and the GraphPad
software package (GraphPad, San Diego, CA). EC50 values (mean ± standard error) represent the concentration at which 50% of the maximal effect
is achieved. Relative efficacies (%) were determined by comparison with the effect produced by a maximal effective concentration of reference agonist
(UDP-glucose, 1) in the same experiment. If no maximal effect is given, then 100% efficacy was achieved. N = 3.
b
Potency at P2Y6 receptor reported in Maruoka et al.,15 Besada et al.,17 and Ko et al.18 Potency at P2Y14 receptor reported in Ko et al.12,13
c
<50% effect at 10 μM.
d
Structure is given below.
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